{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"data_sharing_plan":["IPD Sharing (as of September 2023): No"],"condition":["Neoplasm Metastasis","NSCLC","Colon Cancer","Non-small cell lung cancer","Colorectal Cancer","Advanced Solid Tumors","Advanced Cancer","Pancreatic Cancer","Metastatic Cancer","Neoplasms","Malignant Neoplastic Disease"],"disease":["Neoplasm Metastasis","Nsclc","Colon Cancer","Colorectal Cancer","Advanced Solid Tumors","Non-small Cell Lung Cancer","Advanced Cancer","Pancreatic Cancer","Metastatic Cancer","Neoplasms","Malignant Neoplastic Disease"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2334803"],"location":["United States"],"study_start_month":["4"],"keyword":["SHP2","KRAS G12C","Adagrasib"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)","description":"This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.","dates":{"creation":"2020-04-15"},"accession":"2334803","cross_references":{"ClinicalTrials___gov":["NCT04330664"]}}